ZEAL.CO · PEAD ↓ 79

Zealand Pharma reported Q2 2026 EPS of 55.34 on 2026-08-12, beating the consensus of 21.34 by 34.00 (+159.3%); year-over-year comparison is not available in current data.

Print-day reaction was -1.8% versus the prior close, a muted negative response despite the substantial EPS beat. The overnight gap to the T+1 open recovered sharply, adding +5.8%, suggesting initial after-hours optimism. Over the following two trading days (T+1 close through T+3 close), the stock drifted -7.8%, fully erasing the gap and then some. Cumulative abnormal return of -6.4% versus SPY.US puts this firmly in PEAD short territory — the drift reversed the overnight relief and confirmed sellers in control; per the documented pattern, the read runs through 2026-11-09.